Bevacizumab (Anti-Human VEGF, Humanized Antibody)

Bevacizumab is a humanized monoclonal antibody against VEGF. It specifically binds to VEGF and blocks its binding to the corresponding receptors on the cell surface, thereby inhibiting angiogenesis[1]. Bevacizumab has high affinity for all VEGF-A isoforms and inhibits its interaction with VEGFR-1 and VEGFR-2[2]. Bevacizumab is a targeted therapy drug called an angiogenesis inhibitor that is used to study and treat many types of cancer [3].

In vitro, In vitro, low-concentration Bevacizumab (2-4 mg/ml) treated intranasal endothelial cells in HHT patients, significantly reducing the expression of VEGF after 24 hours, but it increased again after 48 hours, and exceeding 4 mg/ml would produce cytotoxic effects[4]. Bevacizumab (5-1000 ng/mL) does not cause cell death after treating U87-RFP cells for 48 hours [5].

In vivo, Bevacizumab (5 and 25 mg/kg) treated by intraperitoneal injection in mice with orthotopic glioma significantly inhibited the growth rate of tumor blood vessels and improved the survival rate[5]. Intraperitoneal administration of Bevacizumab (5 mg/kg) can prolong the survival of ovarian cancer model mice[6]. Bevacizumab (5mg/kg) showed strong anti-angiogenic activity in the treatment of osteosarcoma model mice[7].

References:
[1] Minckwitz G V , Eidtmann H , Rezai M ,et al.Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer[J].New England Journal of Medicine, 2012.
[2] Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of treatment in ApoE-/-mice. [J]Sci Rep. 2017 Jun 14;7(1):3504.
[3]Pujade-Lauraine.Bevacizumab Combined With Chemotherapy for PlatinumResistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial [J].Journal of Clinical Oncology, 2014.
[4]Haneen Sadick, Elena SchÄfer, Christel Weiss, et al. An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia[J].Experimental and Therapeutic Medicine.July 5, 2022.11493.
[5]Von Baumgarten L , Brucker D , Tirniceru A ,et al. Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells[J].Clinical Cancer Research, 2011, 17(19):6192-205.
[6]Mabuchi S , Terai Y , Morishige K ,et al.Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.[J]Clinical Cancer Research , 2008, 14(23):7781-9.
[7]Zhao Z X , Li X , Liu W D , et al. Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab[J]. Orthopaedic Sugery. 2016.234-240.